Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.
1. A multivalent pneumococcal vaccine composition comprising:
(a) carrier proteins consisting of pneumococcal surface adhesion protein A (PsaA) and CRM 197 ; and
(b) capsular pneumococcal polysaccharides of two or more serotypes,
wherein each of the capsular pneumococcal polysaccharides are individually conjugated to a carrier protein selected from PsaA and CRM 197 ,
wherein at least one capsular pneumococcal polysaccharide is conjugated to PsaA,
wherein at least one capsular pneumococcal polysaccharide is conjugated to CRM 197 ,
wherein the at least one capsular pneumococcal polysaccharide conjugated to PsaA has a serotype different from a serotype of the at least one capsular pneumococcal polysaccharide conjugated to CRM 197 and
wherein the PsaA lacks the wild-type hydrophobic N-terminal leader peptide.
2. The multivalent pneumococcal vaccine composition of claim 1 , wherein the pneumococcal vaccine composition is a 10 valent, 13 valent, 14 valent, 15 valent, 17 valent, 18 valent, 19 valent, 20 valent, 22 valent, 23 valent, 24 valent or 25 valent pneumococcal vaccine composition.
3. The multivalent pneumococcal vaccine composition of claim 1 , the two or more serotypes are selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45.
4. The multivalent pneumococcal vaccine composition of claim 1 having a percent ratio of carrier proteins to capsular pneumococcal polysaccharides (protein/PS) of about 0.5 to about 2.0 protein/PS.
5. The multivalent pneumococcal vaccine composition of claim 1 further comprising a pharmaceutically acceptable carrier.
6. The multivalent pneumococcal composition of claim 1 , further comprising capsular pneumococcal polysaccharides of 10 or more serotypes selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19F, 19A, 20A, 20B, 22F, 23A, 23B, 23F, 24B, 24F, 31, 33F, 34, 35B, 35F, 38, 39 and 45.
7. The pneumococcal vaccine composition of claim 1 wherein the pneumococcal vaccine composition comprises at least 14 pneumococcal polysaccharides, at least 17 pneumococcal polysaccharides, at least 19 pneumococcal polysaccharides, at least 20 pneumococcal polysaccharides, at least 22 pneumococcal polysaccharides, or at least 24 pneumococcal polysaccharides.
8. The pneumococcal vaccine composition of claim 1 comprising (1) pneumococcal polysaccharides of two or more serotypes and a carrier protein, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A and 22F and the carrier protein is PsaA or (2) pneumococcal polysaccharides of two or more serotypes and a carrier protein, wherein the serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 9V, 10A, 12F, 14, 15A, 15B, 18C, 19F, 19A, 22F, 23F, 33F, 34, 35, 38 and 45, and the carrier protein is PsaA.
9. The multivalent pneumococcal vaccine composition of claim 1 , wherein the multivalent pneumococcal vaccine composition is formulated into a dosage unit.
10. The multivalent pneumococcal vaccine composition of claim 9 , wherein the dosage unit comprises about 0.1 μg to about 50 μg, about 0.1 μg to about 10 μg, or about 1 μg to about 5 μg of each capsular pneumococcal polysaccharide, and wherein each of the capsular pneumococcal polysaccharides is individually conjugated to about 1.5 μg to about 5 μg of carrier protein.
11. The multivalent pneumococcal vaccine composition of claim 1 further comprising a pharmaceutically acceptable diluent, buffer, preservative, stabilizer, adjuvant, and/or a lyophilization excipient.
12. The multivalent pneumococcal vaccine composition of claim 9 , wherein the dosage unit is supplied as a unit dose vial, a multiple dose vial, or a pre-filled syringe.
13. The pneumococcal vaccine composition of claim 1 wherein the pneumococcal vaccine composition is a single 0.5 mL dose comprising:
about 2.2 to 4.4 μg of one or more pneumococcal polysaccharides;
about 1 μg to about 10 μg of PsaA conjugated to each of the one or more pneumococcal polysaccharides;
about 1 μg to about 10 μg of CRM 197 conjugated to each of the one or more pneumococcal polysaccharides;
about 0.2 mg to about 1 mg of aluminum phosphate adjuvant; and
an excipient.
14. A method of inducing an immune response in a subject comprising, administering an effective amount of the multivalent pneumococcal vaccine composition of claim 1 to the subject.
15. The method of claim 14 , wherein the subject has a disease mediated by Streptococcus pneumoniae.
16. The method of claim 15 , wherein the disease mediated by Streptococcus pneumoniae is invasive pneumococcal disease (IPD).